Small HER2-positive, node-negative breast cancer: Who should receive systemic adjuvant treatment?

Annals of Oncology

Volumn 22, Issue 1, 2011, Pages 17-23

  Joerger, M ^a   Thurlimann B ^a   Huober, J ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Adjuvant treatment; Breast cancer; HER2 overexpression; Small tumors; Trastuzumab

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; RISK REDUCTION; TUMOR VOLUME;

EID: 78650412892     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq304     Document Type: Review

References (31)

1. Lohrisch C, Piccart M. An overview of HER2. Semin Oncol 2001; 28: 3-11.
2. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
4. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
5. Slamon D, Eiermann W, Robert N. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophophamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in women with Her2neu positive early breast cancer patients: BCIRG 006 study. Cancer Res 2009; 69 (Suppl): (Abst 62) 500S.
6. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29-36.
7. Spielmann M, Roche H, Delozier T et al. Trastuzumab for patients with axillarynode-positive breast cancer: results of the FNCLCC-PACS04 trial. J Clin Oncol 2009; 27: 6129-6134.
8. Perez EA, Romond EH, Suman VJ. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 2007; 25 (Suppl): (Abst 512) 6S.
9. Perez EA, Suman VJ, Davidson NE et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. Cancer Res 2009; 69 (Suppl): (Abst 80).
10. Press MF, Bernstein L, Thomas PA et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in nodenegative breast carcinomas. J Clin Oncol 1997; 15: 2894-2904.
11. Joensuu H, Isola J, Lundin M et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003; 9: 923-930.
12. Black D, Younger J, Martei Y et al. Recurrence risk in T1a-b, nodenegative, HER2 positive breast cancer. Breast Cancer Res Treat 2006; 100: (Abst 2037) S92.
13. Chia S, Norris B, Speers C et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of nodenegative breast cancers. J Clin Oncol 2008; 26: 5697-5704.
14. Gonzalez-Angulo AM, Litton JK, Broglio KR et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1cm or smaller. J Clin Oncol 2009; 27: 5700-5706.
15. Tovey SM, Brown S, Doughty JC et al. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer 2009; 100: 680-683.
16. Curigliano G, Viale G, Bagnardi V et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009; 27: 5693-5699.
17. Park YH, Kim ST, Cho EY et al. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Breast Cancer Res Treat 2010; 119: 653-661.
18. Chavez-MacGregor M, Gonzalez-Angulo AM. HER2-neu positivity in patients with small and node-negative breast cancer (pT1a, b, N0, M0): a high risk group? Clin Adv Hematol Oncol 2009; 7: 591-598.
19. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
20. Untch M, Gelber RD, Jackisch C et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008; 19: 1090-1096.
21. Rodrigues MJ, Wassermann J, Albiges-Sauvin L et al. Treatment of nodenegative infra-centimetric HER2+ invasive breast carcinomas: a joint AERIO/REMAGUS study. J Clin Oncol 2009; 27 (Suppl): (Abst 517).
22. McArthur HL, Morris PG, Patil S et al. Benefits of trastuzumab-based therapy for women with small, node-negative, HER2-positive breast cancer. ASCO Breast Cancer Symposium 2009; (Abst 228).
23. National Comprehensive Cancer Network Practice Guidelines in Oncology-v.2.2010. www.nccn.org (27 May 2010, date last accessed).
24. Burstein HJ, Winer EP. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol 2009; 27: 5671-5673.
25. Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. 2010 www.ago-online.de (27 May 2010, date last accessed).
26. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH et al. Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol 2007; 25: 4952-4960.
27. Colleoni M, Rotmensz N, Peruzzotti G et al. Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. Ann Oncol 2004; 15: 1633-1639.
28. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27: 5529-5537.
29. Johnston S, Pippen J Jr, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27: 5538-5546.
30. Huober J, Fasching P, Paepke S et al. Letrozole in combination with trastuzumab is superior to letrozole monotherapy as first line treatment in patients with hormone-receptor-positive, HER2-positive metastatic breast cancer (MBC)-results of the eLEcTRA Trial. Cancer Res 2009; 69 (Suppl): (Abst 4094) 737S.
31. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 2009; 20: 1319-1329.